Bayer Pharmaceutical Press Release: Nexavar Approved for Medullary Thyroid Cancer in Japan

• March 2, 2016
• 1 min read

On February 29, Bayer Pharmaceutical received regulatory approval in Japan for Nexavar (sorafenib) for the treatment of medullary thyroid cancer. Approximately 29,000 thyroid cancer patients exist in Japan, of whom approximately 5% have medullary thyroid cancer.

Nexavar targets multiple kinases including VEGFR-1, VEGFR-2, VEGFR-3, and PDGFR-B. It had previously received approval in Japan for renal cell carcinoma in January 2008 and for unresectable hepatocellular carcinoma in May 2009. This latest approval for medullary thyroid cancer further broadens the indications for this multikinase inhibitor.

For the full press release, please refer to the following link: http://byl.bayer.co.jp/html/press_release/2016/news2016-02-29.pdf

Thyroid Cancer

• Clinical Trial Medications

  • (Lung Cancer) Phase II results for Topotecan and Topotecan + Berzosertib combination.
  • (Lung Cancer) Efficacy of Enhertu in HER2-mutant non-small cell lung cancer (NSCLC).
  • (Lung Cancer) Clinical outcomes of anti-B7-H3 antibody-drug conjugate DS-7300.

Medical Supporter was formerly certified as an international medical visa guarantor by Japan's Ministry of Foreign Affairs and the Ministry of Economy, Trade and Industry (B-066).

Figure 1

Figure 2

Figure 3

Figure 4

Related Cancer Information

• Lung cancer
• Liver cancer